Keywords: charges, pull, wyeth, earnings, down, pharmaceutical, major
Charges pull Wyeth earnings down 79%
Article | 02 February 2004
US pharmaceutical major Wyeth reported a 14% rise in fourth-quarter 2003 revenues at $4.33 billion. However, due to special charges of $639.9 million for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
